Financials data is unavailable for this security.
View more
Year on year Sangamo Therapeutics Inc had net income fall 34.09% from a loss of 192.28m to a larger loss of 257.83m despite a 58.34% increase in revenues from 111.30m to 176.23m.
Gross margin | -- |
---|---|
Net profit margin | -2,033.68% |
Operating margin | -2,093.97% |
Return on assets | -119.44% |
---|---|
Return on equity | -194.05% |
Return on investment | -153.51% |
More ▼
Cash flow in USDView more
In 2023, cash reserves at Sangamo Therapeutics Inc fell by 55.24m. However, Cash Flow from Investing totalled 153.53m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 224.84m for operations while cash generated from financing totalled 14.59m.
Cash flow per share | -1.30 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1138 |
---|---|
Tangible book value per share | 0.1138 |
More ▼
Balance sheet in USDView more
Current ratio | 1.03 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼